VASC

DIABETES, SGLT2I AND HEART FAILURE: AN ESSENTIAL PRIMER

Presenter(s)

• 

  Subodh Verma, MD, PhD, FRCSC, FAHA

  Cardiac Surgeon
  University of Toronto

Learning Objectives

At the conclusion of this session, participants will be able to:

• to recognize that HF is a clinically significant comorbidity in diabetes; and
• to highlight the latest trial findings on SGLT2 inhibition in HF.